POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium, the major intracellular cation, essential for nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride maintains electrolyte balance.
| Metabolism | Potassium is primarily excreted by the kidneys; dextrose undergoes cellular metabolism; sodium chloride is renally regulated. |
| Excretion | Primarily renal (90% or more) as potassium ions; minimal biliary or fecal elimination (<10%). Excretion is directly correlated with glomerular filtration and tubular handling. |
| Half-life | Approximately 2–4 hours for potassium in the plasma; however, the terminal half-life is not clinically meaningful as potassium is tightly regulated. The redistribution and elimination half-life is about 12–16 hours from the whole body, with a slowly exchanging pool. Clinical context: In renal impairment, half-life is prolonged. |
| Protein binding | Negligible; potassium is not significantly bound to plasma proteins (<1% bound). |
| Volume of Distribution | Approximately 0.5 L/kg (range 0.4–0.6 L/kg). This reflects distribution primarily into the intracellular space (98% of total body potassium is intracellular). Clinical meaning: Large Vd indicates extensive tissue uptake; rapid distribution occurs from plasma into cells via Na+/K+ ATPase. |
| Bioavailability | Intravenous: 100% (given as an infusion directly into the bloodstream). Oral: Not applicable for this formulation; enteral absorption is ~90% from dietary sources but not relevant for this IV product. |
| Onset of Action | Intravenous administration: Immediate (within seconds to minutes) as potassium is infused directly into circulation; clinical effect on serum potassium levels is rapid. The rate depends on infusion speed. |
| Duration of Action | Intravenous: Duration of effect on serum potassium lasts for 1–2 hours after infusion stops, but total body repletion may require longer. Maintenance of normal levels depends on ongoing intake and renal function. |
| Molecular Weight | 74.55 |
Intravenous infusion of 10-20 mEq/hour, not to exceed 40 mEq/hour or 200 mEq per 24 hours. Typical dose 30 mEq in 1000 mL of D5 0.225% NaCl at a rate of 100 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: use with caution, monitor serum potassium; GFR <10 mL/min: avoid use unless dialysis is available and frequent monitoring is performed. |
| Liver impairment | No specific adjustment required; use with caution in severe hepatic impairment due to risk of electrolyte imbalances. |
| Pediatric use | Intravenous: 0.5-1 mEq/kg/dose, not to exceed 30 mEq per dose; administer at a rate not exceeding 0.5 mEq/kg/hour. |
| Geriatric use | Start at lower end of dosing range (5-10 mEq/hour) due to age-related renal function decline and increased risk of hyperkalemia; monitor closely. |
| 1st trimester | Potassium chloride is generally considered safe in pregnancy when used at recommended doses. No increased risk of major malformations has been reported. Use only if clearly needed. |
| 2nd trimester | Safe for use at recommended doses. Potassium requirements may increase during pregnancy; monitor serum potassium levels. |
| 3rd trimester | Safe for use. Hypokalemia treatment is important to prevent maternal complications. Use with caution in preeclampsia due to potential renal impairment. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium crosses the placenta via active transport to maintain fetal homeostasis. Fetal serum potassium is higher than maternal. No significant risk at therapeutic doses. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Administration of potassium chloride is compatible with breastfeeding. Monitor infant for electrolyte disturbances if maternal doses are high. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride is not teratogenic. No fetal risks are associated with potassium administration at standard doses. However, hyperkalemia from excessive dosing may cause fetal arrhythmias. Dextrose and sodium chloride are considered safe in pregnancy. No trimester-specific risks identified. |
| Fetal Monitoring | Monitor serum potassium, glucose, and sodium levels regularly. Assess for signs of hyperkalemia (ECG changes, muscle weakness). Fetal heart rate monitoring if maternal electrolyte disturbances occur. Monitor maternal fluid status for volume overload, especially in preeclampsia. |
| Fertility Effects | No known effects on fertility. Potassium chloride does not impair reproductive function. Dextrose and sodium chloride have no adverse effects on fertility. |
■ FDA Black Box Warning
No FDA black box warning specific to this combination product.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or azotemiaUntreated Addison's diseaseAdynamic ileus or bowel obstructionConcurrent use of potassium-sparing diuretics (unless carefully monitored)
| Precautions | Risk of hyperkalemia, especially in renal impairment, Monitor serum potassium, glucose, and electrolytes, Rapid infusion may cause hyperkalemia and cardiac arrest, Use with caution in patients with heart failure, renal failure, or adrenal insufficiency |
| Food/Dietary | Concurrent use of potassium-sparing diuretics, ACE inhibitors, or ARBs increases hyperkalemia risk; avoid high-potassium foods (bananas, oranges, spinach, salt substitutes) unless directed. Dextrose content may require meal timing adjustments in diabetic patients to prevent hypoglycemia. Sodium restriction is generally not required with 0.225% NaCl unless specified. |
| Clinical Pearls | This combination therapy (potassium 30 mEq in D5 0.225% NaCl) is hypertonic (approximately 525 mOsm/L) and must be administered via central line to avoid peripheral phlebitis. Rate of potassium infusion should not exceed 10 mEq/hour for non-emergent repletion; continuous cardiac monitoring is required during administration. Dextrose 5% may cause hyperglycemia in insulin-dependent patients; adjust insulin accordingly. Sodium chloride 0.225% provides minimal sodium (approx. 17 mEq/L) and is suitable for patients with fluid restriction or hyponatremia risk. |
| Patient Advice | This medication is given through a large vein in your chest or neck to prevent vein irritation. · Tell your nurse immediately if you feel burning, pain, or redness near the IV site. · You will have your heart rhythm monitored continuously while receiving this infusion. · Report any symptoms such as muscle weakness, tingling, or irregular heartbeat. · If you have diabetes, your blood sugar will be checked frequently due to the dextrose content. |
Loading safety data…